Correction to: Phase 2 Open-Label Trial Investigating Percutaneous Laser Ablation for Treatment of Early-Stage Breast Cancer: MRI, Pathology, and Outcome Correlations

被引：0

作者：

Barbara Schwartzberg

John Lewin

Osama Abdelatif

Jacqueline Bernard

Hanadi Bu-Ali

Simon Cawthorn

Margaret Chen-Seetoo

Sheldon Feldman

Sasirekha Govindarajulu

Lyn Jones

Arne Juette

Sanjay Kavia

Robert Maganini

Simon Pain

Mike Shere

Craig Shriver

Simon Smith

Alexandra Valencia

Eric Whitacre

Roger Whitney

机构：

[1] Sarah Cannon Research Institute at Rose Medical Center,

[2] Women’s Imaging Center,undefined

[3] Tucson Pathology Associates,undefined

[4] Walter Reed National Military Medical Center,undefined

[5] Virginia Piper Cancer Institute,undefined

[6] Southmead Hospital,undefined

[7] Herbert Irving Pavilion,undefined

[8] Columbia University,undefined

[9] Montefiore Einstein Center for Cancer Care,undefined

[10] Norfolk and Norwich University Hospital,undefined

[11] Broomfield Hospital,undefined

[12] St. Alexius Breast Care Center,undefined

[13] Breast Center of Southern Arizona,undefined

来源：

Annals of Surgical Oncology | 2018年 / 25卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

The article “Phase 2 Open-Label Trial Investigating Percutaneous Laser Ablation for Treatment of Early-Stage Breast Cancer: MRI, Pathology, and Outcome Correlations”, written by Barbara Schwartzberg et al., was originally published electronically on the publisher’s internet portal (currently SpringerLink) on July 9, 2018, without open access.

引用

页码：998 / 998

共 50 条

[41] PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17) : a multicentre, open-label, randomised, phase 3 trial
Borchmann, Peter
Plutschow, Annette
Kobe, Carsten
Greil, Richard
Meissner, Julia
Topp, Max S.
Ostermann, Helmut
Dierlamm, Judith
Mohm, Johannes
Thiemer, Julia
Sokler, Martin
Kerkhoff, Andrea
Ahlborn, Miriam
Halbsguth, Teresa, V
Martin, Sonja
Keller, Ulrich
Balabanov, Stefan
Pabst, Thomas
Vogelhuber, Martin
Huttmann, Andreas
Wilhelm, Martin
Zijlstra, Josee M.
Moccia, Alden
Kuhnert, Georg
Brockelmann, Paul J.
von Tresckow, Bastian
Fuchs, Michael
Klimm, Beate
Rosenwald, Andreas
Eich, Hans
Baues, Christian
Marnitz, Simone
Hallek, Michael
Diehl, Volker
Dietlein, Markus
Engert, Andreas
LANCET ONCOLOGY, 2021, 22 (02): : 223 - 234
[42] (Trial in Progress) A phase 2, open-label, randomized multicenter trial to evaluate neoadjuvant lasofoxifene in molecularly-selected HR+/HER2-Clinical Stage 2/3 breast cancer
Chien, J.
Esserman, L.
Elias, A.
Wei, M.
Plourde, P.
Portman, D.
BREAST, 2023, 68 : S66 - S66
[43] Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer
Chan, Arlene
Shannon, Catherine
de Boer, Richard
Baron-Hay, Sally
Redfern, Andrew
Bauwens, Astrid
Craft, Paul
Webb, Suzanne
Townsend, Amanda
Kotasek, Dusan
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (04) : 368 - 375
[44] Treatment of Breast Cancer-Related Lymphedema With Topical Tacrolimus: A Prospective, Open-Label, Single- Arm, Phase II Pilot Trial
Hansen, Frederik C. Gulmark
Jorgensen, Mads Gustaf
Sorensen, Jens Ahm
JOURNAL OF BREAST CANCER, 2023, 26 (01) : 46 - 59
[45] Pamiparib as consolidation treatment after concurrent chemoradiotherapy of limited-stage small cell lung cancer: a single-arm, open-label phase 2 trial
Mao, Jiuang
Ni, Jianjiao
Chu, Li
Chu, Xiao
Xu, Dayu
Yang, Xi
Zhu, Zhengfei
RADIATION ONCOLOGY, 2024, 19 (01)
[46] Apatinib combined with docetaxel and platinum as neoadjuvant treatment for triple-negative/HER2-positive breast cancer: A randomized, open-label, multicenter, phase 2 trial
Liu, Yunjiang
Zhang, Shuo
CANCER RESEARCH, 2020, 80 (04)
[47] Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
Schmid, P.
Salgado, R.
Park, Y. H.
Munoz-Couselo, E.
Kim, S. B.
Sohn, J.
Im, S. -A.
Foukakis, T.
Kuemmel, S.
Dent, R.
Yin, L.
Wang, A.
Tryfonidis, K.
Karantza, V.
Cortes, J.
Loi, S.
ANNALS OF ONCOLOGY, 2020, 31 (05) : 569 - 581
[48] Neoadjuvant docetaxel plus carboplatin versus epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label, phase II trial.
Zhang, Liulu
Wu, Zhiyong
Lin, Ying
Li, Jie
Liu, Zhenzhen
Cao, Yin
Zhang, Gangling
Gao, Hong-Fei
Yang, Mei
Yang, Ci-Qiu
Zhu, Teng
Cheng, Min-Yi
Ji, Fei
Li, Jieqing
Wang, Kun
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[49] Neoadjuvant docetaxel plus cisplatin versus docetaxel plus doxorubicin and cyclophosphamide in early-stage triple-negative breast cancer (HNBC-001): results from a multicenter, randomized controlled, open-label phase II trial
Jiao, Dechuang
Qiao, Jianghua
Wang, Chengzheng
Li, Juntao
Sun, Xianfu
Lu, Zhenduo
Zhang, Chongjian
Li, Lianfang
Yan, Min
Feng, Yueqing
Zhou, Yong
Deng, Miao
Liu, Xinlan
Ma, Mingde
Jia, Haiquan
Xia, Qingxin
Chen, Xiuchun
Liu, Zhenzhen
CANCER RESEARCH, 2024, 84 (09)
[50] Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial
Nederlof, Iris
Isaeva, Olga I.
de Graaf, Manon
Gielen, Robbert C. A. M.
Bakker, Noor A. M.
Rolfes, Adrianne L.
Garner, Hannah
Boeckx, Bram
Traets, Joleen J. H.
Mandjes, Ingrid A. M.
de Maaker, Michiel
van Brussel, Thomas
Chelushkin, Maksim
Champanhet, Elisa
Lopez-Yurda, Marta
van de Vijver, Koen
van den Berg, Jose G.
Hofland, Ingrid
Klioueva, Natasja
Mann, Ritse M.
Loo, Claudette E.
van Duijnhoven, Frederieke H.
Skinner, Victoria
Luykx, Sylvia
Kerver, Emile
Kalashnikova, Ekaterina
van Dongen, Marloes G. J.
Sonke, Gabe S.
Linn, Sabine C.
Blank, Christian U.
de Visser, Karin E.
Salgado, Roberto
Wessels, Lodewyk F. A.
Drukker, Caroline A.
Schumacher, Ton N.
Horlings, Hugo M.
Lambrechts, Diether
Kok, Marleen
NATURE MEDICINE, 2024, 30 (11) : 3223 - 3235

← 1 2 3 4 5 →